ArticleEMBO reports2018
Sirt1 protects from K-Ras-driven lung carcinogenesis.
Open access · bronzeAbstract read
In one paragraph
Article in EMBO reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- USP28 Promotes Osimertinib Resistance in H1975 NSCLC Cells by Deubiquitinating and Stabilizing SIRT1.The Kaohsiung journal of medical sciences · 2026Article
- Immunometabolic reprogramming in lung cancer: interplay between immune and stem-like cells in immune checkpoint inhibitor resistance.Journal of translational medicine · 2025Review
- Senotherapy for chronic lung disease.Pharmacological reviews · 2025Review
- SLC29A1 and SLC29A2 are human nicotinamide cell membrane transporters.Nature communications · 2025Article
- Emerging role of sirtuins in non‑small cell lung cancer (Review).Oncology reports · 2024Review
- Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.Experimental & molecular medicine · 2023Article
- Role of Post-translational Modification of Silent Mating Type Information Regulator 2 Homolog 1 in Cancer and Other Disorders.Journal of cancer prevention · 2022Review
- From targeted therapy to a novel way: Immunogenic cell death in lung cancer.Frontiers in medicine · 2022Review
- Review
- ERK Dephosphorylation through MKP1 Deacetylation by SIRT1 Attenuates RAS-Driven Tumorigenesis.Cancers · 2020Article
- SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop.Cell death & disease · 2020Article
- The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.Frontiers in cell and developmental biology · 2020Review
- Avenanthramide C suppresses hypoxia-induced cyclooxygenase-2 expression through sirtuin1 activation in non-small-cell lung cancer cells.Animal cells and systems · 2020Article
- Review
- The sirtuin family in cancer.Cell cycle (Georgetown, Tex.) · 2019Article
- Subcellular compartmentalization of NADPharmacology & therapeutics · 2019Review
- Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 3 countries.
Luis Filipe Costa-MachadoBioactive Products and Metabolic Syndrome Group - BIOPROMET, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain.
Roberto Martín-HernándezGENYAL Nutrigenomic Platform, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain.
Miguel Ángel Sanchez-LuengoFlow Cytometry Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Katharina HessTumor Suppression Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Claudia Vales-VillamarinBioactive Products and Metabolic Syndrome Group - BIOPROMET, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain.ORCID 0000-0002-4060-7187
Marta BarradasBioactive Products and Metabolic Syndrome Group - BIOPROMET, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain.
Cian LynchTumor Suppression Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Daniel de la NavaBioactive Products and Metabolic Syndrome Group - BIOPROMET, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain.
Alberto Diaz-RuizTranslational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Rafael de CaboTranslational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Marta CañameroHistopathology Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Lola MartinezFlow Cytometry Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
Marta Sanchez-CarbayoTranslational Oncology Lab, Lucio Lascaray Research Center, University of the Basque Country, Vitoria-Gasteiz, Spain.
Daniel HerranzTumor Suppression Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain dh710@cinj.rutgers.edu manuel.serrano@irbbarcelona.org pablojose.fernandez@imdea.org.ORCID 0000-0003-1768-5969
Manuel SerranoTumor Suppression Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain dh710@cinj.rutgers.edu manuel.serrano@irbbarcelona.org pablojose.fernandez@imdea.org.ORCID 0000-0001-7177-9312
Pablo J Fernandez-MarcosBioactive Products and Metabolic Syndrome Group - BIOPROMET, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain dh710@cinj.rutgers.edu manuel.serrano@irbbarcelona.org pablojose.fernandez@imdea.org.ORCID 0000-0003-3515-4125
Madrid Institute for Advanced Studies · ESSpanish National Cancer Research Centre · ESInstitució Catalana de Recerca i Estudis Avançats · ESRutgers, The State University of New Jersey · USUniversity of the Basque Country · ES
Funding
Calorie restriction and agingZIAAG000368 · NIA · NATIONAL INSTITUTE ON AGING · PI DE CABO, RAFAEL · 2009 to 2025
$6.9MFunctional dissection of oncogenic enhancersR00CA197869 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI HERRANZ, DANIEL · 2017 to 2019
$747kFunctional dissection of oncogenic enhancersK99CA197869 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HERRANZ, DANIEL · 2015 to 2016
$342kNCI NIH HHS K99 CA197869NCI NIH HHS R00 CA197869
Abstract
The NAD
Indexed as
Adenocarcinoma of LungAlveolar Epithelial CellsAnimalsCarcinogenesisCarcinoma, Non-Small-Cell LungCell Line, TumorCells, CulturedDown-RegulationFibroblastsHumansLung NeoplasmsMiceMitogen-Activated Protein KinasesMolecular Targeted TherapyMutationPhosphatidylinositol 3-KinasesHras protein, mouseKRAS protein, humanMitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)SIRT1 protein, humanSirt1 protein, mouseSirtuin 1K‐RASnon‐small cell lung carcinomaSIRT1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.